Immunohistochemical (IHC) PTK7 scoring regimens and methods for adjunctive cancer therapy
By using specific antibody staining and microscopic observation at different magnifications to calculate the tumor proportion score (TPS), the objectivity and accuracy issues of PTK7 expression scoring in existing IHC methods were resolved, enabling effective prediction of cancer and selection of treatment options.
CN120813841APending Publication Date: 2025-10-17AGILENT TECHNOLOGIES INC
1 Cites 0 Cited by
Patent Information
- Application Number
- CN202480019407.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-03-22
- Filing Date
- 2024-03-21
- Publication Date
- 2025-10-17
AI Technical Summary
Technical Problem
Existing immunohistochemistry (IHC) methods lack objective and accurate scoring methods when evaluating PTK7 expression, making it difficult to accurately predict the occurrence and prognosis of cancer.
Method used
Tissue samples were stained with an antibody that specifically binds to PTK7. The intensity and proportion of anti-PTK7 cell staining were determined by microscopic observation under different magnifications, and the tumor proportion score (TPS) was calculated to objectively evaluate the expression level of PTK7.
Benefits of technology
It provides a robust, reliable, reproducible and accurate scoring method that can better predict the occurrence and prognosis of cancer and help choose appropriate treatment options.
✦ Generated by Eureka AI based on patent content.
Abstract
In alternative embodiments, provided are immunohistochemical (IHC) methods and kits for reproducibly determining and scoring the degree of expression of protein tyrosine protein kinase-like 7 (PTK7), also known as colon cancer kinase 4 (CCK4), in a tissue sample; hER2 or a receptor tyrosine protein kinase erbB-2, or a cluster of differentiation 340 (CD340); a programmed death ligand 1 (PD-L1) or a differentiation cluster 274 (CD274); a B7 homolog 1 (B7-H1); and Ki-67 or MKI67 (a proliferation marker Ki-67), as well as a use thereof. In alternative embodiments, methods and kits are provided for diagnosing or selecting an individual eligible for treatment with a cancer or tumor therapeutic agent, or assessing the risk of cancer or tumor recurrence using an IHC method as provided herein. In alternative embodiments, kits comprising components and instructions for performing the methods as provided herein are provided. Described herein are methods for scoring PTK7 expression and utilizing the score as a companion or supplemental diagnosis to help treat or ameliorate cancer or tumor.
Need to check novelty before this filing date? Find Prior Art